View Report Details Global I.V. Iron Drugs Market Report ----------------------------------------2016
View Report Details Executive Summary Iron is vital for multiple bodily functions, most importantly for the production of hemoglobin for red blood cells which are responsible for transporting oxygen in the blood. As an element, the only source of iron is from the diet. There is no way the body can produce iron itself. Intravenous (IV) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. The first iron product for intravenous use was high-molecular-weight iron dextran. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron. The key factors driving growth of the global I.V. iron industry include increase in number of dialysis cases, increasing global healthcare expenditures, rising ageing population, increasing life expectancy rate, growing number of ERSD patients and rising medicines expenditures. Some of the noteworthy trends and developments of this industry are new product development, introduction of the first generation drugs InFed (iron dextran) and Dexeferrum (iron dextra) and feraccru treatment penetration. However, the growth of this sector is being hindered by emerging anemia management therapies and associated risks. The report analyzes the global iron products industry along with an extensive coverage of global, Europe and the US I.V. iron market. The global IV iron market witnesses intense competition with numerous top notch players; such as Galenica Pharmaceuticals, Actavis Inc, AMAG Pharmaceuticals; operating in the marketplace along with small budding players. As a part of analysis of fierce competition prevailing in the industry, product contention has been presented in the report. The company profiles of leading aforementioned players in the market are also incorporated in the report. By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Growing number of dialysis patients, ageing population and ERSD patients to drive the market…
US$ Million
Global I.V. Iron Drugs Market by Value (2010-2015) The global I.V. iron market was valued at US$... million in 2015, as compared to US$... million in 2013, showing an incline of … %. As of 2015, in terms of product category, Venofer accounted for the largest market share of …% in the global I.V. iron market, followed by Ferinject with …% of the market share. ISS and Feraheme held …% and …% share of the total respectively. As of 2015, oral iron products held the largest share of …% share in the global iron products market, followed by intravenous products with share of …%.
2010
2011
2012
2013
2014
2015
Global I.V. Iron Drugs Market Share by Product (2015)
Global Iron Products Market Share by Segment (2015)
Increasing healthcare expenditure and economic development are also driving the market….
US$ Million
The US I.V. Iron Drug Market by Value (2010-2015)
The US I.V. iron market marked an incline of …% to reach US$... million in 2015, as compared to US$... million in the prior year. As of 2015, Venofer accounted for the largest market share of …% in the total US I.V. iron market followed by Injectafer with share of …%. Feraheme and Gluconate held …% and …% share respectively. As of 2015, European I.V. iron drug market declined by …% to reach US$... million, due to currency fluctuation.
2010
2011
2012
2013
2014
2015
The US I.V. Iron Drug Market Share by Product (2015) US$ Million
European I.V. Iron Drug Market by Value (2010-2015)
2010
2011
2012
2013
2014
2015
The future growth would mainly be driven by growing ERSD patients, increasing cases of hypertension and number of dialysis patients.
US$ Million
Global I.V. Iron Drug Market Forecast (2014-2019E)
2014
2015
2016E
2017E
2018E
2019E
•
The global I.V. iron drugs market is estimated to grow at a CAGR of …% from US$... million in 2014 to US$... million in 2019.
•
The global I.V. iron drugs market is showing a significant growth owing to improvement in the quality of treatment outside dialysis, increasing number of dialysis patients, growing number of ERSD patients worldwide and growing ageing population.
Contact Us: View Report Details These are abridged and sanitized sample pages from the comprehensive report on the “ Global I.V. Iron Drugs Market ” . To know more about this report or for any customized research requirement, please contact the following:
Koncept Analytics
Vikas Gupta BD Manager
CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T. +91-120-4130959 C: +91-9811715635 vikas@konceptanalytics.com
www.konceptanalytics.com